Clinical Trial Update: IMFINZI Study in Patients With Extensive Stage Small Cell Lung Cancer

View source ↗

Summary

A study evaluating durvalumab (Imfinzi) in patients with extensive-stage small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)

Snippet

Sponsor: AstraZeneca | Conditions: Carcinoma, Small Cell | Status: COMPLETED